第1章 目錄

第2章 簡介

第3章 疾病概要

病因·病理生理學

病因

病理生理學

預測

QOL

症狀

第4章 疾病的管理

概要

治療概要

帕金森氏症的評估規模

第5章 競爭評估

概要

策略性競爭企業的評估

產品簡介 - COMT抑制劑

第6章 Stalevo/Comtan(entacapone)

概要

功效

安全性

SWOT分析

預測

第7章 附錄

圖表

目錄

Product Code: GDHC392DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Comtan (entacapone) was developed by Orion for Parkinson's disease patients who experience end-of-dose wearing-off. The product, known as Comtan, is co-marketed with Novartis across the US, certain European markets, Brazil, and Japan. Orion has exclusive rights to the Nordic and Baltic countries, where the company is based, the UK, Ireland, and Germany, and is known as Comtess in these markets. Comtan/Comtess was first approved and launched in Europe in 1998, and launched a year later in the US. Additionally, entacapone is one of the active ingredients in Stalevo, a triple-combination pill with carbidopa, levodopa, and entacapone, co-marketed with Novartis.

Scope

Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Stalevo including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Stalevo for the top eight countries from 2012 to 2022.